476 related articles for article (PubMed ID: 35831153)
1. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
Hao Y; Yang YL; Wang YC; Li J
Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
[TBL] [Abstract][Full Text] [Related]
2. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
Liu Y; Han B
Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients.
Jin ZL; He T; Peng L; Wu XY; Fan D; Chen M; Fan YZ; Guo YL; Lu ZB; Wang HR
Curr Med Sci; 2023 Dec; 43(6):1206-1212. PubMed ID: 37755635
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9.
Ferri N; Ruscica M; Lupo MG; Vicenzi M; Sirtori CR; Corsini A
Pharmacol Res; 2022 Oct; 184():106439. PubMed ID: 36100012
[TBL] [Abstract][Full Text] [Related]
8. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
[TBL] [Abstract][Full Text] [Related]
9. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
[TBL] [Abstract][Full Text] [Related]
10. Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Zhang Y; Zhang Y; Zhang B; Chen Z; Wei Y; Chen P; Chang C; Liu G; Chen K; Ding J; Jiang Z
Clin Ther; 2022 Jun; 44(6):901-912. PubMed ID: 35581018
[TBL] [Abstract][Full Text] [Related]
11. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC; Windecker S; Pedrazzini G; Mueller C; Cook S; Matter CM; Muller O; Häner J; Gencer B; Crljenica C; Amini P; Deckarm O; Iglesias JF; Räber L; Heg D; Mach F
J Am Coll Cardiol; 2019 Nov; 74(20):2452-2462. PubMed ID: 31479722
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y
Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364
[TBL] [Abstract][Full Text] [Related]
15. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
[TBL] [Abstract][Full Text] [Related]
18. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
20. Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
Nguy J; Hitchen SA; Lan NSR; Dwivedi G; Larbalestier R; Yeap BB; Fegan PG
Intern Med J; 2023 Jun; 53(6):994-1001. PubMed ID: 35112773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
